Wow. A list of sponsors for the trial locations who will be considered authors in any fluff piece like the last just for signing their name, even if they saw zero benefit in their patients on the treatment at their site.
If the mos of 5 years was bumped to 13 percent (obviously based on selection criteria) then 87 percent were at the sites where these people running the trial watched them pass away with no benefit, given there were 50 sites and Liau probably has a large majority at UCLA and Ashkan the majority in Europe.
So what are these authors at the other sites gonna say? "I had two patients and saw no benefit". Nope. They will say nothing and get author credit in a "scientific" paper.
Market Data 
Markets 
AI
